Advantages of a third-generation β-blocker in patients with diabetes mellitus
- 6 May 2004
- journal article
- review article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 93 (9), 49-52
- https://doi.org/10.1016/j.amjcard.2004.01.026
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Use of Beta Blockers in the Patient With DiabetesThe Endocrinologist, 2003
- Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery diseaseAmerican Journal Of Medicine, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Association between C-reactive protein and features of the metabolic syndrome: a population-based study.Diabetes Care, 2000
- β-Adrenergic Blocking Agents in Patients With Diabetes—Friend and FoeEndocrine Practice, 1999
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionThe New England Journal of Medicine, 1998
- Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitusBMJ, 1997
- Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.Cardiovascular Research, 1997
- Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery diseaseThe American Journal of Cardiology, 1996
- Diabetic patients and beta-blockers after acute myocardial infarctionEuropean Heart Journal, 1990